Aprogen Pharmaceuticals Inc (003060) — Cash Flow-to-Debt Ratio
Aprogen Pharmaceuticals Inc (003060) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of ₩-7.66 Billion could theoretically repay 0% of its total liabilities (₩288.27 Billion) in one year. See 003060 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aprogen Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for Aprogen Pharmaceuticals Inc across 13 annual periods. Also explore Aprogen Pharmaceuticals Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Aprogen Pharmaceuticals Inc (2010–2024)
Year-by-year debt coverage analysis for Aprogen Pharmaceuticals Inc. For market capitalisation and broader financial context, see Aprogen Pharmaceuticals Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.15x | ₩-31.00 Billion | ₩212.29 Billion | ▲ +4.2% |
| 2023 | -0.15x | ₩-33.65 Billion | ₩220.71 Billion | ▼ -203.0% |
| 2022 | 0.15x | ₩25.73 Billion | ₩173.73 Billion | ▲ +141.5% |
| 2021 | -0.36x | ₩-6.23 Billion | ₩17.44 Billion | ▼ -174.8% |
| 2020 | 0.48x | ₩8.09 Billion | ₩16.95 Billion | ▲ +1079.5% |
| 2019 | 0.04x | ₩713.73 Million | ₩17.65 Billion | ▲ +102.2% |
| 2018 | 0.02x | ₩1.33 Billion | ₩66.55 Billion | ▲ +118.0% |
| 2017 | -0.11x | ₩-8.93 Billion | ₩80.41 Billion | ▼ -1347.7% |
| 2016 | 0.01x | ₩449.98 Million | ₩50.57 Billion | ▼ -91.6% |
| 2015 | 0.11x | ₩1.85 Billion | ₩17.48 Billion | ▲ +134.7% |
| 2014 | -0.30x | ₩-6.92 Billion | ₩22.71 Billion | ▼ -288.5% |
| 2013 | -0.08x | ₩-1.70 Billion | ₩21.71 Billion | ▼ -1234.7% |
| 2010 | 0.01x | ₩247.92 Million | ₩35.89 Billion | — |